Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort
Movement Disorders Clinical Practice · 29.10.2026
DOI: 10.1002/mdc3.70888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 29.10.2026. Verfasst von Silvia Gallo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Friedreich ataxia (FRDA) is a rare, inherited neurodegenerative disorder. Omaveloxolone is the first disease‐modifying treatment approved for FRDA. To date, real‐world data remain limited.
Objectives
To report short‐term efficacy and safety data from a real‐world FRDA cohort of advanced patients and explore potential predictors of treatment response.
Methods
We conducted a prospective study on 27 consecutive genetically‐confirmed FRDA patients treated with Omaveloxolone for 3–6 months. Scores at the modified Friedreich‐Ataxia‐Rating‐Scale (mFARS), peripheral neuropathy severity, cardiac involvement, cognitive‐affective syndrome, ambulatory status, and the presence of pes cavus were assessed at baseline. Wilcoxon test was used to compare baseline vs. follow‐up mFARS scores. mFARS changes in ambulatory and non‐ambulatory patients were evaluated using a two‐way ANOVA. Patient Global Impression of Change (PGI‐C) was collected and adverse events (AEs) and laboratory data monitored.
Results
Twenty‐six patients (median age and disease duration 42.5 and 24.5 years respectively) remained on therapy for at least 3 months. Total mFARS scores improved by 1.5 points ( P = 0.007), with significant changes in the subscore of lower limb coordination (−1.5, P = 0.022). PGI‐C indicated a perception of improvement in 42.3% of patients. Baseline demographic‐clinical features did not correlate with the percentage improvement in mFARS score, and no differences were observed between ambulatory and non‐ambulatory patients. No serious AEs occurred.
Conclusions
Our findings support the efficacy and safety of Omaveloxolone in a real‐world setting, being in line with data observed in the MOXIe trial, although our cohort is highly different in terms of age, disease duration, and severity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
- Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
- SC Neurologia 2U, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
- Clinical Psychology Unit, AOU Città Della Salute e Della Scienza di Torino, Corso Bramante 88, Turin, Italy.
ORCID-Profile: Silvia Gallo, Carlo Alberto Artusi, Claudia Ledda, Gabriele Imbalzano, Francesca Donetto, Maurizio Zibetti, Marco Bozzali
Zitieren
APA
Gallo, S., Artusi, C. A., Ledda, C., Budicin, S., Imbalzano, G., Buzzelli, C., Scaglia, E., Donetto, F., Montanaro, E., Romagnolo, A., Zibetti, M., Rizzone, M. G., Bozzali, M., & Lopiano, L. (2026). Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70888
Vancouver
Gallo S, Artusi CA, Ledda C, Budicin S, Imbalzano G, Buzzelli C, et al. Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70888
BibTeX
@article{Gallo2026,
author = {Gallo, Silvia and Artusi, Carlo Alberto and Ledda, Claudia and Budicin, Serena and Imbalzano, Gabriele and Buzzelli, Cecilia and Scaglia, Elena and Donetto, Francesca and Montanaro, Elisa and Romagnolo, Alberto and Zibetti, Maurizio and Rizzone, Mario Giorgio and Bozzali, Marco and Lopiano, Leonardo},
title = {Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70888}
}
EUVIMED